Clinical trials: Burkitt's Lymphoma
Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
The aim of the trial is to evaluate the molecular characteristics and MDD/MRD of B-NHL in pediatric patients in order to identify on the one hand the very high risk group and to prescribe them more intensive treatment on the…
- Conditions
- Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma, Primary Mediastinal Lymphoma, Primary CNS Lymphoma
- Trial name
- NCT05518383
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying how well rituximab works in preventing acute graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for hematologic cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT01044745
- Testing
- rituximab, mycophenolate mofetil, tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003331
- Testing
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00290641
- Testing
- filgrastim, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Burkitt Lymphoma
Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents with relapsed and refractory B-cell NHL/L3ALL.
- Trial name
- NCT00180895
- Testing
- Rituximab
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
CCCG-ALL2025 LR-B-ALL plan is designed based on the CCCG-ALL2020 plan. This is a clinical trial using 14 days of blinatumomab (Blina-14) as early intensification after induction therapy and 2nd Blina-14 in consolidation therapy…
- Conditions
- Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
- Trial name
- CCCG-LR-B-ALL (NCT06882057)
- Testing
- Blinatumomab, Reinduction-2 omission, Chemo-light Maintenance 2
- Where
- 27 sites in China, Hong Kong
- Volunteers
- 3,000 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia, Fanconi Anemia, Graft Versus Host Disease
- Trial name
- NCT00290628
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
Drugs used in chemotherapy, such as FAU, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00769288
- Testing
- 2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01116154
- Testing
- lenalidomide, vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Leukemia
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
The goal of this clinical research study is to learn if IPI-145 can help to control the disease in patients with ALL. The safety of the study drug will also be studied.
- Trial name
- NCT02028039
- Testing
- IPI-145, Follow-up Visit/Call
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients
RATIONALE: Understanding the emotional needs of spouses or others who are living with and caring for patients who have undergone stem cell transplantation may help improve the quality of life of both the caregivers and the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00082654
- Testing
- psychosocial assessment and care
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent intermediate-grade or high-grade non-Hodgkin's lymphoma or mantle cell lymphoma.
- Trial name
- NCT00003039
- Testing
- alvocidib
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
NHL, Large Cell Lymphoma
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Background: One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person.
- Conditions
- NHL, Large Cell Lymphoma, Follicular Lymphoma, ALL
- Trial name
- NCT02315612
- Testing
- CD22-CAR
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- National Cancer Institute (NCI)
B-cell Acute Lymphoblastic Leukemia
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
Hypotheses: The Investigator hypothesizes that targeting ALL cells with 2 different modalities, ie liposomal vincristine sulfate as a microtubule inhibitor and blinatumomab as a BITE immuno-oncology therapy, will have at least…
- Trial name
- NCT04448834
- Testing
- Blinatumomab
- Where
- 3 sites in United States
- Sponsor
- Dorothy Sipkins, MD, PhD
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic…
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT03007147
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide
- Where
- 226 sites in United States, Australia and 17 more
- Volunteers
- 352 people
- Sponsor
- Children's Oncology Group
Leukemia, Lymphoma
Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Adjusting the dose of drugs used in chemotherapy such as cyclophosphamide may decrease side effects while stopping cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00062140
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
This study will determine the safety and applicability of experimental forms of umbilical cord blood (UCB) transplantation for patients with high risk hematologic malignancies who might benefit from a hematopoietic stem cell…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01652014
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Non-Hodgkin Lymphoma, Burkitt's Lymphoma
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1) and dose expansion (Part 2).
- Conditions
- Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT02669017
- Testing
- ADCT-402
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 183 people
- Sponsor
- ADC Therapeutics S.A.